マーケットレポート詳細

抗炎症薬の世界市場：2031年予測

Anti-inflammatory Therapeutics Market (Drug Class: Anti-inflammatory Biologics, NSAIDs, and Others; Application: Auto-immune Diseases, Respiratory Conditions, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版元：Transparency Market Research 　 出版元について
発行年：2023年10月
定価 ：Single User License(1名様ライセンス)US$5,795(米国ドル)/Multi User License(5名様)$8,795 /Enterprise License $11,705
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文236ページになります。
商品コード：TMR091

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

抗炎症薬の世界市場規模は2022年で946億ドル、2031年に1495億ドル、市場の平均年成長率は5.1%になる見込みです。

当レポートでは、抗炎症薬の市場予測-2031年、各種セグメント別市場分析(薬剤クラス別、用途別、国地域別、等)、COVID-19の影響分析、競合状況、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

■抗炎症薬の世界市場予測2017-2031年

・市場規模(US$)

■薬剤クラス別、市場-2031年

抗炎症生物製剤
非ステロイド性抗炎症薬（NSAIDs）
その他
※(市場規模US$)

■用途別、市場-2031年

自己免疫疾患
・関節リウマチ
・乾癬
・多発性硬化症
・クローン病
・潰瘍性大腸炎
・その他

呼吸器疾患
・COPD（慢性閉塞性肺疾患）
・喘息
その他
※(市場規模US$)

■投与経路別、市場-2031年

経口
注射
局所
吸入
※(市場規模US$)

■流通経路別、市場-2031年

病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2031年

北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
南米
・ブラジル、メキシコ
・その他南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析

市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析

■抗炎症薬の主要企業プロフィール動向

AbbVie, Inc.
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Pfizer, Inc.
Novartis AG
GlaxoSmithKline plc.
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
AstraZeneca
Sanofi

（全236頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

1. Preface

    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-inflammatory Therapeutics Market
4. Market Overview

    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis
    5.2. List of Biologicals Used to Treat Chronic Autoimmune and Inflammatory Diseases
    5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.4. COVID-19 Pandemic Impact on Industry

6. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. Anti-inflammatory Biologics
        6.3.2. NSAIDs
        6.3.3. Others
    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Auto-immune Diseases
            7.3.1.1. Rheumatoid Arthritis
            7.3.1.2. Psoriasis
            7.3.1.3. Multiple Sclerosis
            7.3.1.4. Crohn's Disease
            7.3.1.5. Ulcerative Colitis
            7.3.1.6. Others
        7.3.2. Respiratory Conditions
            7.3.2.1. COPD
            7.3.2.2. Asthma
    7.4. Market Attractiveness Analysis, by Application

8. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Route of Administration, 2017–2031
        8.3.1. Oral
        8.3.2. Injection
        8.3.3. Topical
        8.3.4. Inhalation
    8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Anti-inflammatory Therapeutics Market Analysis and Forecast, by Region

    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017–2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region

11. North America Anti-inflammatory Therapeutics Market Analysis and Forecast

    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017–2031
        11.2.1. Anti-inflammatory Biologics
        11.2.2. NSAIDs
        11.2.3. Others
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Auto-immune Diseases
            11.3.1.1. Rheumatoid Arthritis
            11.3.1.2. Psoriasis
            11.3.1.3. Multiple Sclerosis
            11.3.1.4. Crohn's Disease
            11.3.1.5. Ulcerative Colitis
            11.3.1.6. Others
        11.3.2. Respiratory Conditions
            11.3.2.1. COPD
            11.3.2.2. Asthma
    11.4. Market Value Forecast, by Route of Administration, 2017–2031
        11.4.1. Oral
        11.4.2. Injection
        11.4.3. Topical
        11.4.4. Inhalation
    11.5. Market Value Forecast, by Distribution Channel, 2017–2031
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Class
        11.7.2. By Application
        11.7.3. By Route of Administration
        11.7.4. By Distribution Channel
        11.7.5. By Country/Sub-region

12. Europe Anti-inflammatory Therapeutics Market Analysis and Forecast

    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017–2031
        12.2.1. Anti-inflammatory Biologics
        12.2.2. NSAIDs
        12.2.3. Others
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Auto-immune Diseases
            12.3.1.1. Rheumatoid Arthritis
            12.3.1.2. Psoriasis
            12.3.1.3. Multiple Sclerosis
            12.3.1.4. Crohn's Disease
            12.3.1.5. Ulcerative Colitis
            12.3.1.6. Others
        12.3.2. Respiratory Conditions
            12.3.2.1. COPD
            12.3.2.2. Asthma
    12.4. Market Value Forecast, by Route of Administration, 2017–2031
        12.4.1. Oral
        12.4.2. Injection
        12.4.3. Topical
        12.4.4. Inhalation
    12.5. Market Value Forecast, by Distribution Channel, 2017–2031
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Class
        12.7.2. By Application
        12.7.3. By Route of Administration
        12.7.4. By Distribution Channel
        12.7.5. By Country/Sub-region

13. Asia Pacific Anti-inflammatory Therapeutics Market Analysis and Forecast

    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017–2031
        13.2.1. Anti-inflammatory Biologics
        13.2.2. NSAIDs
        13.2.3. Others
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Auto-immune Diseases
            13.3.1.1. Rheumatoid Arthritis
            13.3.1.2. Psoriasis
            13.3.1.3. Multiple Sclerosis
            13.3.1.4. Crohn's Disease
            13.3.1.5. Ulcerative Colitis
            13.3.1.6. Others
        13.3.2. Respiratory Conditions
            13.3.2.1. COPD
            13.3.2.2. Asthma
    13.4. Market Value Forecast, by Route of Administration, 2017–2031
        13.4.1. Oral
        13.4.2. Injection
        13.4.3. Topical
        13.4.4. Inhalation
    13.5. Market Value Forecast, by Distribution Channel, 2017–2031
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Class
        13.7.2. By Application
        13.7.3. By Route of Administration
        13.7.4. By Distribution Channel
        13.7.5. By Country/Sub-region

14. Latin America Anti-inflammatory Therapeutics Market Analysis and Forecast

    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017–2031
        14.2.1. Anti-inflammatory Biologics
        14.2.2. NSAIDs
        14.2.3. Others
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Auto-immune Diseases
            14.3.1.1. Rheumatoid Arthritis
            14.3.1.2. Psoriasis
            14.3.1.3. Multiple Sclerosis
            14.3.1.4. Crohn's Disease
            14.3.1.5. Ulcerative Colitis
            14.3.1.6. Others
        14.3.2. Respiratory Conditions
            14.3.2.1. COPD
            14.3.2.2. Asthma
    14.4. Market Value Forecast, by Route of Administration, 2017–2031
        14.4.1. Oral
        14.4.2. Injection
        14.4.3. Topical
        14.4.4. Inhalation
    14.5. Market Value Forecast, by Distribution Channel, 2017–2031
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Class
        14.7.2. By Application
        14.7.3. By Route of Administration
        14.7.4. By Distribution Channel
        14.7.5. By Country/Sub-region

15. Middle East & Africa Anti-inflammatory Therapeutics Market Analysis and Forecast

    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Class, 2017–2031
        15.2.1. Anti-inflammatory Biologics
        15.2.2. NSAIDs
        15.2.3. Others
    15.3. Market Value Forecast, by Application, 2017–2031
        15.3.1. Auto-immune Diseases
            15.3.1.1. Rheumatoid Arthritis
            15.3.1.2. Psoriasis
            15.3.1.3. Multiple Sclerosis
            15.3.1.4. Crohn's Disease
            15.3.1.5. Ulcerative Colitis
            15.3.1.6. Others
        15.3.2. Respiratory Conditions
            15.3.2.1. COPD
            15.3.2.2. Asthma
    15.4. Market Value Forecast, by Route of Administration, 2017–2031
        15.4.1. Oral
        15.4.2. Injection
        15.4.3. Topical
        15.4.4. Inhalation
    15.5. Market Value Forecast, by Distribution Channel, 2017–2031
        15.5.1. Hospital Pharmacies
        15.5.2. Retail Pharmacies
        15.5.3. Online Pharmacies
    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Drug Class
        15.7.2. By Application
        15.7.3. By Route of Administration
        15.7.4. By Distribution Channel
        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. AbbVie, Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Merck & Co., Inc.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Johnson & Johnson Services, Inc.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Pfizer, Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Novartis AG
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. GlaxoSmithKline plc
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Amgen, Inc.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. F. Hoffmann-La Roche Ltd.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. AstraZeneca
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Sanofi
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031

Table 03: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 05: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 08: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031

Table 09: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 10: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 11: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 13: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031

Table 14: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 15: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 18: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031

Table 19: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 20: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031

Table 24: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 25: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 26: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 28: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017‒2031

Table 29: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 30: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Anti-inflammatory Therapeutics Market Value Share, by Drug Class, 2022

Figure 03: Global Anti-inflammatory Therapeutics Market Value Share, by Application, 2022

Figure 04: Global Anti-inflammatory Therapeutics Market Value Share, by Route of Administration, 2022

Figure 05: Global Anti-inflammatory Therapeutics Market Value Share, by Distribution Channel, 2022

Figure 06: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 07: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 08: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

Figure 09: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031

Figure 10: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 11: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 12: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 13: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 14: Global Anti-inflammatory Therapeutics Market Value Share Analysis, by Region, 2022 and 2031

Figure 15: Global Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Region, 2023–2031

Figure 16: North America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 17: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

Figure 18: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

Figure 19: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 20: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 21: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

Figure 22: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031

Figure 23: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 24: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 25: North America Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 26: North America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 28: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 29: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 30: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 32: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

Figure 33: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031

Figure 34: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 35: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 36: Europe Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 37: Europe Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 38: Asia Pacific Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 39: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 40: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 41: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 42: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

Figure 44: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031

Figure 45: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 46: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 47: Asia Pacific Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 48: Asia Pacific Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 49: Latin America Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 50: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 51: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 52: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 53: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 54: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

Figure 55: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 56: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 57: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 58: Latin America Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 59: Latin America Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 60: Middle East & Africa Anti-inflammatory Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 61: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 62: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 63: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 64: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 65: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Application, 2022 and 2031

Figure 66: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Application 2023–2031

Figure 67: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 68: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 69: Middle East & Africa Anti-inflammatory Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 70: Middle East & Africa Anti-inflammatory Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 71: Global Anti-inflammatory Therapeutics Market Share Analysis, by Company (2022)

△ 一番上に戻る